

Press Release – For Immediate Release

Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina

Global pharmaceutical company chooses Tar Heel State to invest \$100 million in first U.S. manufacturing site, with plans for further North Carolina Expansion

Paramus, NJ; October 30, 2018 – Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the official inauguration of its manufacturing site in Monroe, North Carolina. The Monroe facility will serve as the first manufacturing site for Glenmark in the United States, and the company anticipates the site will grow well beyond its current 168 employees. The Glenmark site is the largest pharmaceutical manufacturer in the Charlotte region.¹

“Our investment in Monroe is a key priority for Glenmark, and contributing to the surrounding community through high-quality job creation and educational investments is a critical success factor as we expand our global manufacturing operations into the U.S.,” said Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals. “We have a commitment to long-term growth and expansion in North Carolina and are thankful for the mutual support from our community partners in helping realize those goals.”

U.S. Senator Burr weighs in on Glenmark’s investment in North Carolina by adding, “North Carolina is a high-growth state that continues to attract innovative companies from all over the globe. Our world class research universities, skilled workforce and vibrant local communities make this the perfect place to conduct cutting-edge research and invest in high-skilled jobs. It is a winning formula, and one North Carolinians can be proud of.”

In partnership with the South Piedmont Community College, Glenmark has helped design and fund a training program to facilitate learning and development on technical, safety, leadership and process improvement tools and techniques for all employees. To date, more than 200 people have been trained through this program.

“Glenmark Pharmaceuticals’ decision to build this facility in Union County is a testament to the readiness of our highly skilled manufacturing workforce, which fulfills their needs for quality and safety in the production of a wide variety of drug formulations,” states Chris Platé, Executive Director of Monroe-Union County Economic Development. “As Union County’s first pharmaceutical facility, Glenmark brings economic growth, increased diversity and employment opportunities that strengthen our community’s broad manufacturing sector.”

With more than 100,000 square feet, the Monroe, North Carolina facility is designed to manufacture a variety of fixed dose pharmaceutical formulations. Glenmark has invested more than \$100 million into the facility with plans for further expansion in the coming years. At peak capacity, the site is anticipated to produce 300-400 million tablets and capsules, 20-25 million vials and pre-filled syringes and 25-30 million ampoules for inhaled formulations. Globally, Glenmark has 16 world class manufacturing facilities across four continents operating under Good Manufacturing Practices (GMP) to ensure quality and safety, nine of which are registered with the U.S. Food and Drug Administration.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology. Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit glenmarkpharma-us.com.

For further information, please contact:

An Phan
+1-201-331-4218

Isha Trivedi
+91-22-4018-9801
corpcomm@glenmarkpharma.com

¹ SOURCE: North Carolina Biotechnology Center